FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319455243> ?p ?o ?g. }

• W4319455243 endingPage "e159" @default.
• W4319455243 startingPage "e153" @default.
• W4319455243 abstract "We aimed to evaluate the impact of 18 F-fluciclovine PET/CT imaging on failure-free survival (FFS) post-salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence.Seventy-nine patients were recruited in a phase 2/3 clinical trial to undergo 18 F-fluciclovine PET/CT before SRT for PCa. Four patients with extrapelvic disease were excluded. All patients were followed up at regular intervals up to 48 months. Treatment failure was defined as a serum prostate-specific antigen level of ≥0.2 ng/mL above the nadir after SRT, confirmed with an additional measurement, requiring systemic treatment or clinical progression. Failure-free survival was computed and compared between patients grouped according to 18 F-fluciclovine PET/CT imaging findings.Eighty percent (60/75) of patients had a positive finding on 18 F-fluciclovine PET/CT, of which 56.7% (34/60) had prostate bed-only uptake, whereas 43.3% (26/60) had pelvic nodal ± bed uptake. Following SRT, disease failure was detected in 36% (27/75) of patients. There was a significant difference in FFS between patients who had a positive versus negative scan (62.3% vs 92.9% [ P < 0.001] at 36 months and 59.4% vs 92.9% [ P < 0.001] at 48 months). Similarly, there was a significant difference in FFS between patients with uptake in pelvic nodes ± bed versus prostate bed only at 36 months (49.8% vs 70.7%; P = 0.003) and at 48 months (49.8% vs 65.6%; P = 0.040). Failure-free survival was also significantly higher in patients with either negative PET/CT or prostate bed-only disease versus those with pelvic nodal ± prostate bed disease at 36 (78% vs 49.8%, P < 0.001) and 48 months (74.4% vs 49.8%, P < 0.001).Findings on pre-SRT 18 F-fluciclovine PET/CT imaging, even when acted upon to optimize the treatment decisions and treatment planning, are predictive of post-SRT FFS in men who experience PCa recurrence after radical prostatectomy. A negative 18 F-fluciclovine PET/CT is most predictive of a lower risk of failure, whereas the presence of pelvic nodal recurrence portends a higher risk of SRT failure." @default.
• W4319455243 created "2023-02-09" @default.
• W4319455243 creator A5001234431 @default.
• W4319455243 creator A5010114692 @default.
• W4319455243 creator A5013832255 @default.
• W4319455243 creator A5016217510 @default.
• W4319455243 creator A5019379036 @default.
• W4319455243 creator A5022407431 @default.
• W4319455243 creator A5024852113 @default.
• W4319455243 creator A5029766244 @default.
• W4319455243 creator A5032305403 @default.
• W4319455243 creator A5036023937 @default.
• W4319455243 creator A5040880164 @default.
• W4319455243 creator A5057397331 @default.
• W4319455243 creator A5061066145 @default.
• W4319455243 creator A5080498027 @default.
• W4319455243 creator A5081519486 @default.
• W4319455243 creator A5087391476 @default.
• W4319455243 creator A5088821236 @default.
• W4319455243 date "2023-02-08" @default.
• W4319455243 modified "2023-10-03" @default.
• W4319455243 title "Impact of 18F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy" @default.
• W4319455243 cites W1953875133 @default.
• W4319455243 cites W1972667933 @default.
• W4319455243 cites W1984350421 @default.
• W4319455243 cites W2032988677 @default.
• W4319455243 cites W2148032552 @default.
• W4319455243 cites W2257635864 @default.
• W4319455243 cites W2293822080 @default.
• W4319455243 cites W2510755861 @default.
• W4319455243 cites W2767882393 @default.
• W4319455243 cites W2883030921 @default.
• W4319455243 cites W2898544959 @default.
• W4319455243 cites W2913023403 @default.
• W4319455243 cites W2924617625 @default.
• W4319455243 cites W2949281899 @default.
• W4319455243 cites W2989413482 @default.
• W4319455243 cites W3014488270 @default.
• W4319455243 cites W3128667695 @default.
• W4319455243 cites W3128992128 @default.
• W4319455243 cites W3139707937 @default.
• W4319455243 cites W3159813235 @default.
• W4319455243 cites W3189412006 @default.
• W4319455243 cites W3190529761 @default.
• W4319455243 cites W3197990792 @default.
• W4319455243 cites W3203540255 @default.
• W4319455243 cites W3205404566 @default.
• W4319455243 cites W4225126675 @default.
• W4319455243 cites W4281617140 @default.
• W4319455243 cites W3171958405 @default.
• W4319455243 doi "https://doi.org/10.1097/rlu.0000000000004590" @default.
• W4319455243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36754362" @default.
• W4319455243 hasPublicationYear "2023" @default.
• W4319455243 type Work @default.
• W4319455243 citedByCount "3" @default.
• W4319455243 countsByYear W43194552432023 @default.
• W4319455243 crossrefType "journal-article" @default.
• W4319455243 hasAuthorship W4319455243A5001234431 @default.
• W4319455243 hasAuthorship W4319455243A5010114692 @default.
• W4319455243 hasAuthorship W4319455243A5013832255 @default.
• W4319455243 hasAuthorship W4319455243A5016217510 @default.
• W4319455243 hasAuthorship W4319455243A5019379036 @default.
• W4319455243 hasAuthorship W4319455243A5022407431 @default.
• W4319455243 hasAuthorship W4319455243A5024852113 @default.
• W4319455243 hasAuthorship W4319455243A5029766244 @default.
• W4319455243 hasAuthorship W4319455243A5032305403 @default.
• W4319455243 hasAuthorship W4319455243A5036023937 @default.
• W4319455243 hasAuthorship W4319455243A5040880164 @default.
• W4319455243 hasAuthorship W4319455243A5057397331 @default.
• W4319455243 hasAuthorship W4319455243A5061066145 @default.
• W4319455243 hasAuthorship W4319455243A5080498027 @default.
• W4319455243 hasAuthorship W4319455243A5081519486 @default.
• W4319455243 hasAuthorship W4319455243A5087391476 @default.
• W4319455243 hasAuthorship W4319455243A5088821236 @default.
• W4319455243 hasConcept C121608353 @default.
• W4319455243 hasConcept C126322002 @default.
• W4319455243 hasConcept C126894567 @default.
• W4319455243 hasConcept C127077266 @default.
• W4319455243 hasConcept C141071460 @default.
• W4319455243 hasConcept C2775842073 @default.
• W4319455243 hasConcept C2776235491 @default.
• W4319455243 hasConcept C2776694085 @default.
• W4319455243 hasConcept C2777008409 @default.
• W4319455243 hasConcept C2779466945 @default.
• W4319455243 hasConcept C2780192828 @default.
• W4319455243 hasConcept C2780775027 @default.
• W4319455243 hasConcept C2989005 @default.
• W4319455243 hasConcept C509974204 @default.
• W4319455243 hasConcept C71924100 @default.
• W4319455243 hasConceptScore W4319455243C121608353 @default.
• W4319455243 hasConceptScore W4319455243C126322002 @default.
• W4319455243 hasConceptScore W4319455243C126894567 @default.
• W4319455243 hasConceptScore W4319455243C127077266 @default.
• W4319455243 hasConceptScore W4319455243C141071460 @default.
• W4319455243 hasConceptScore W4319455243C2775842073 @default.
• W4319455243 hasConceptScore W4319455243C2776235491 @default.
• W4319455243 hasConceptScore W4319455243C2776694085 @default.
• W4319455243 hasConceptScore W4319455243C2777008409 @default.

• next